TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24126611

Group type: EXPERIMENTAL
Intervention: Exercise training and behavioral weight loss (750 vs. >3000 kcal/week)
Number of subjects: 46
Study: 21084988

Group type: EXPERIMENTAL
Intervention: Variceal band ligation (VBL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate injection (CI)
Number of subjects: 38
Study: 18306109

Group type: EXPERIMENTAL
Intervention: 3 g Hsp-G administered every morning for 12 weeks (n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo administered every morning for 12 weeks (n = 10)
Number of subjects: 19
Study: 17186321

Group type: EXPERIMENTAL
Intervention: Moderate concentration contrast medium (300 mg I/ml)
Number of subjects: 945

Group type: COMPARATOR
Intervention: High concentration contrast medium (370 mg I/ml)
Number of subjects: 945
Study: 12707842

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy programme (16 group sessions of 90 min each)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy programme
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 122
Study: 10977001

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5‐0.75 microg/day) for 2 years
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5‐0.75 microg/day) for 12 months followed by calcium for 12 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5‐0.75 microg/day)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Calcitriol therapy
Number of subjects: 65
Study: 9358940

Group type: EXPERIMENTAL
Intervention: O + M + MPZ
Number of subjects: 338

Group type: COMPARATOR
Intervention: O + M
Number of subjects: 338
Study: 1490453

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Iopentol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 60
Study: 3885979

Group type: EXPERIMENTAL
Intervention: Intravenous timolol (54 patients)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (52 patients)
Number of subjects: 106
Study: 31128568

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29402341

Group type: EXPERIMENTAL
Intervention: 19AL (finished indoors on concentrates ad libitum for 100 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 19SP (finished at pasture supplemented with 5 kg DM of concentrate per head daily for 100 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 19LP (finished at pasture supplemented with 5 kg DM of concentrate per head daily for 150 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 24MO (finished indoors over the second winter on grass silage ad libitum plus 5 kg DM of concentrate per head daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 21SP (finished at pasture, supplemented with 5 kg DM of concentrate per head daily for 60 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 21LP (finished at pasture, supplemented with 5 kg DM of concentrate per head daily for 110 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 21LP
Number of subjects: 90
Study: 27691979

Group type: EXPERIMENTAL
Intervention: Child maltreatment (maltreated children)
Number of subjects: 548
Study: 24933799

Group type: EXPERIMENTAL
Intervention: Test Dentifrice containing 8% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate (MFP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Dentifrice (silica-based) containing 1450 ppm fluoride as sodium monofluorophosphate (MFP)
Number of subjects: 30
Study: 22357140

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin 1.8 mg/m² intravenously over 1 hour every 3-4 weeks (initially 1.3 mg/m² for first three adults and three children)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (first course 1.3 mg/m²)
Number of subjects: 49
Study: 19962744

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17356305

Group type: EXPERIMENTAL
Intervention: Induction of early meconium evacuation by routine glycerin enema
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no early meconium evacuation)
Number of subjects: 0
Study: 15848699

Group type: EXPERIMENTAL
Intervention: Daclizumab dosing strategies
Number of subjects: 297

Group type: COMPARATOR
Intervention: No antibody induction
Number of subjects: 297
Study: 11990212

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 921

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 921
Study: 9523410

Group type: EXPERIMENTAL
Intervention: Self-promotion in female targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-effacement in male targets
Number of subjects: 0
Study: 7648980

Group type: EXPERIMENTAL
Intervention: Aspirin 350 mg/day for two weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspirin 1400 mg/day for two weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2744905

Group type: EXPERIMENTAL
Intervention: Intracoronary nicardipine (0.4 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29845901

Group type: EXPERIMENTAL
Intervention: Store-based dietary intervention
Number of subjects: 148
Study: 28629471

Group type: EXPERIMENTAL
Intervention: Nutritional and agricultural support activities alongside the routine provision of Save the Children's ECD programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group attending CBCCs supported by Save the Children's Early Childhood Health and Development (ECD) programme
Number of subjects: 60
Study: 25898472

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) progesterone in oil 100 mg daily
Number of subjects: 584

Group type: COMPARATOR
Intervention: Oral micronized progesterone followed by compounded vaginal progesterone 200 mg 3 times daily (OV)
Number of subjects: 584
Study: 23141881

Group type: EXPERIMENTAL
Intervention: THC/CBD oromucosal spray (n=39)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: THC oromucosal spray (n=4)
Number of subjects: 43
Study: 20363847

Group type: EXPERIMENTAL
Intervention: CPAP 5 cm H(2)O
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CPAP 10 cm H(2)O
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CPAP 15 cm H(2)O
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 11
Study: 18699801

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 microg twice daily for 14 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16912977

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (5-FU)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Er:YAG laser resurfacing
Number of subjects: 55
Study: 12809168

Group type: EXPERIMENTAL
Intervention: Individualized, low-volume and moderate-intensity exercise training (IET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-specific, high-volume, low-intensity exercise training (NET)
Number of subjects: 30
Study: 10917990

Group type: EXPERIMENTAL
Intervention: Pruitt-Inahara shunt
Number of subjects: 548
Study: 8815753

Group type: EXPERIMENTAL
Intervention: Combination therapy (methylprednisolone and cyclophosphamide)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 82

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Combination therapy vs Methylprednisolone
Number of subjects: 82
Study: 1519208

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1,200 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 6395276

Group type: EXPERIMENTAL
Intervention: Cefonicid (1.0 g once daily intramuscularly or intravenously)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cefazolin (0.5‐1.0 g three times a day intramuscularly or intravenously)
Number of subjects: 57
Study: 30925575

Group type: EXPERIMENTAL
Intervention: Trabeculectomy augmented by MMC and beta radiation (1000 cGy, strontium-90 probe, 5-7 days preoperatively)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trabeculectomy with MMC alone
Number of subjects: 50
Study: 28064099

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Programme (ERP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Traditional postoperative care
Number of subjects: 86
Study: 26795772

Group type: EXPERIMENTAL
Intervention: Empowerment approach training
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 103
Study: 24766062

Group type: COMPARATOR
Intervention: Primary care treatment
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Secondary care treatment
Number of subjects: 1300
Study: 22437282

Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament reconstruction (MPFLR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medial retinaculum plication (MRP)
Number of subjects: 100
Study: 19160053

Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program dissemination
Number of subjects: 18

Group type: COMPARATOR
Intervention: Services-as-usual control condition
Number of subjects: 18
Study: 16769235

Group type: EXPERIMENTAL
Intervention: Paroxetine (PXT) 30 mg tid for two weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 14740955

Group type: EXPERIMENTAL
Intervention: Formulations 1-15 (10^5-6 PFU/dose or 10^3.5-4.5 PFU/dose)
Number of subjects: 64
Study: 10766487

Group type: EXPERIMENTAL
Intervention: Participation of patients with cancer (experimental group)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Patients with other diagnoses (control group)
Number of subjects: 233
Study: 9467328

Group type: EXPERIMENTAL
Intervention: Combined phototherapy/low-intensity laser therapy (CLILT) at 2.5 Hz
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined phototherapy/low-intensity laser therapy (CLILT) at 5 Hz
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined phototherapy/low-intensity laser therapy (CLILT) at 20 Hz
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 1593244

Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine system
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo system
Number of subjects: 186
Study: 3914023

Group type: EXPERIMENTAL
Intervention: PGI2 infusion (10 mg/kg.min for 24 hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Solvent (glycine buffer)
Number of subjects: 14
Study: 30590701

Group type: EXPERIMENTAL
Intervention: AGO2 loading with G-rich sequences
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: AGO1 loading with GAC motif
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Human Ago2 loading
Number of subjects: 2
Study: 30269054

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 177
Study: 27445558

Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Chest Transillumination (CTR)
Number of subjects: 49
Study: 24999670

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Wait-list Control (WL)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT)
Number of subjects: 87
Study: 22744848

Group type: EXPERIMENTAL
Intervention: Folliculo-luteal function (FLF) normalized preconceptionally
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 19931154

Group type: EXPERIMENTAL
Intervention: Propofol (loading dose of 1 mg/kg over 15 minutes followed by maintenance of 1 to 3 mg/kg per hour)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexmedetomidine (loading dose of 1 microg/kg over 10 minutes followed by maintenance of 0.2 to 2.5 microg/kg per hour)
Number of subjects: 40
Study: 17707724

Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate vaginal gel
Number of subjects: 54

Group type: COMPARATOR
Intervention: K-Y Jelly
Number of subjects: 54
Study: 16369716

Group type: EXPERIMENTAL
Intervention: Double gloving indicator underglove system (IUS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 100
Study: 12792790

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR (460 mg/m(2)/day) + PSK (3 g/day)
Number of subjects: 558

Group type: COMPARATOR
Intervention: 5‐FU (115 mg/m(2)/day) + PSK (3 g/day)
Number of subjects: 558
Study: 10958722

Group type: EXPERIMENTAL
Intervention: Transparent film dressing for 2 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: No dressing
Number of subjects: 100
Study: 8781697

Group type: EXPERIMENTAL
Intervention: 3 mg of vaginal prostaglandin E2 as outpatient treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Expectant management with twice weekly surveillance tests
Number of subjects: 200
Study: 1486421

Group type: EXPERIMENTAL
Intervention: POSSUM
Number of subjects: 117

Group type: COMPARATOR
Intervention: APACHE II
Number of subjects: 117
Study: 6729259

Group type: EXPERIMENTAL
Intervention: Choline theophyllinate, 600 mg orally
Number of subjects: 19
Study: 31898323

Group type: EXPERIMENTAL
Intervention: REACH forgiveness collectivistic (REACH-FC) intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waiting list (WL) control
Number of subjects: 97
Study: 30171349

Group type: EXPERIMENTAL
Intervention: REHIT (2×20 s 'all-out' sprints, time commitment 10 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MICT (30 min of continuous exercise)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HIIT (10×1 min at 90 HRmax, time commitment 25 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: REHIT
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MICT
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 11

Group type: COMPARATOR
Intervention: CON (no exercise)
Number of subjects: 11
Study: 27476505

Group type: EXPERIMENTAL
Intervention: Trained tutors
Number of subjects: 197
Study: 24999104

Group type: EXPERIMENTAL
Intervention: Common atropine (CA) gel
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Modified atropine (MA) gel
Number of subjects: 18
Study: 23316285

Group type: EXPERIMENTAL
Intervention: Low-output LV pacing (Lo)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-output LV pacing (Hi)
Number of subjects: 39
Study: 20033622

Group type: EXPERIMENTAL
Intervention: Guided Care (GC)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 904
Study: 18821457

Group type: EXPERIMENTAL
Intervention: Participants with symptoms consistent with Cluster B pathology
Number of subjects: 54

Group type: COMPARATOR
Intervention: Participants without Cluster B pathology
Number of subjects: 54
Study: 16020076

Group type: EXPERIMENTAL
Intervention: Walking program (16-week duration)
Number of subjects: 10
Study: 12445065

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted resection
Number of subjects: 170

Group type: COMPARATOR
Intervention: Open operation
Number of subjects: 170
Study: 10442679

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitor as first-line treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretic added to ACE inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol (beta-blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors, diuretics, beta-blockers (e.g. carvedilol), and digoxin
Number of subjects: 0
Study: 8557009

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide at 620 micrograms kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide at 930 micrograms kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 20
Study: 1837629

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6262702

Group type: EXPERIMENTAL
Intervention: Tiapride infusion
Number of subjects: 0
Study: 30668228

Group type: EXPERIMENTAL
Intervention: Telephonic diabetes support intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comprehensive face-to-face care
Number of subjects: 0
Study: 28697769

Group type: EXPERIMENTAL
Intervention: Enhanced nurse-delivered intervention (IPV screening, supportive referrals, health/safety risk assessments at baseline and a booster session after 3 months)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Enhanced nurse-delivered intervention
Number of subjects: 950

Group type: COMPARATOR
Intervention: Control group (screening and referral card from nurses)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 950
Study: 25119117

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Patient-controlled opioid-based analgesia (PCA)
Number of subjects: 128
Study: 23256148

Group type: EXPERIMENTAL
Intervention: Child HIV infection, preterm birth, stunting, and wasting
Number of subjects: 311
Study: 21242784

Group type: EXPERIMENTAL
Intervention: 0.02% Mitomycin C (MMC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 28
Study: 18324601

Group type: EXPERIMENTAL
Intervention: Combined programme (intensive psychosocial relapse-prevention + anxiety treatment with cognitive behavioural therapy and optional SSRI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intensive psychosocial relapse-prevention programme only
Number of subjects: 96
Study: 16606474

Group type: EXPERIMENTAL
Intervention: Hematocrit of 20% during normothermic CPB
Number of subjects: 54

Group type: COMPARATOR
Intervention: Hematocrit of 25% during normothermic CPB
Number of subjects: 54
Study: 12957248

Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation (STAD) for 3 months
Number of subjects: 296

Group type: COMPARATOR
Intervention: RT dose <75 Gy + STAD (Group A)
Number of subjects: 296

Group type: COMPARATOR
Intervention: RT dose >=75 Gy alone (Group B)
Number of subjects: 296
Study: 10897156

Group type: EXPERIMENTAL
Intervention: Rectal administration of lamotrigine (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral administration of lamotrigine (100 mg)
Number of subjects: 12
Study: 8847295

Group type: EXPERIMENTAL
Intervention: rhEPO (500 IU.kg‐1.wk‐1 for 6 wk)
Number of subjects: 14

Group type: COMPARATOR
Intervention: rhEPO (100 IU/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Adults (control group)
Number of subjects: 14
Study: 1570385

Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide administered during acquisition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0
Study: 3880523

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Atropine (0.04 mg/kg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Edrophonium (10 mg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg orally) and Edrophonium (10 mg i.v.)
Number of subjects: 6
Study: 30402987

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29976193

Group type: EXPERIMENTAL
Intervention: Social and Therapeutic Horticulture (STH) intervention with 6 monthly sessions led by horticulturists and a psychotherapist
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wellbeing Check Cards
Number of subjects: 36
Study: 26965019

Group type: EXPERIMENTAL
Intervention: Patients aged ≤45 years
Number of subjects: 795

Group type: COMPARATOR
Intervention: Patients aged >45 years
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Age as a predictor of MACE
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 795
Study: 24742508

Group type: EXPERIMENTAL
Intervention: 15 °C normal saline nasal irrigation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 25 °C normal saline nasal irrigation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 °C normal saline nasal irrigation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (20 healthy individuals)
Number of subjects: 60
Study: 24349486

Group type: EXPERIMENTAL
Intervention: Textured insoles
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Smooth insoles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no insoles)
Number of subjects: 40
Study: 20598993

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment before PCI
Number of subjects: 2014
Study: 18240191

Group type: EXPERIMENTAL
Intervention: Intensive exercise therapy (IET)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 85
Study: 16953999

Group type: EXPERIMENTAL
Intervention: Training intervention to improve the management of obesity in primary care
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 23
Study: 14735555

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin alfa and Placebo
Number of subjects: 0
Study: 11889647

Group type: EXPERIMENTAL
Intervention: Physical self-regulation training (PSR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard dental care (SDC)
Number of subjects: 44
Study: 11245027

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with CP (cisplatin + cyclophosphamide) or CAP (CP + adriamycin) regimen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (CP, CAP, or CEP, E = VP16)
Number of subjects: 18